Danazol therapy for idiopathic thrombocytopenic purpura (ITP)

G. Nalli, M. R. Sajeva, G. Carnevale Maffe, E. Ascari

Research output: Contribution to journalArticlepeer-review


Fourteen patients with idiopathic thrombocytopenic purpura (ITP) refractory to steroids and/or splenectomy were treated with Danazol (200 mg 3 times a day), an androgen with reduced virilizing capacity. After a two-month trial with this drug 5 patients experienced a sustained increase in platelet count. In 3 cases remission lasted more than 12 months and in 2 others it was transient. The drug was well-tolerated in all cases; one patient showed worsening of bleeding due to activation of fibrinolysis.

Original languageEnglish
Pages (from-to)55-57
Number of pages3
Issue number1
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Danazol therapy for idiopathic thrombocytopenic purpura (ITP)'. Together they form a unique fingerprint.

Cite this